Abstract
The management of pediatric abdominopelvic angiosarcoma remains unclear due to limited clinical experience. Herein, we presented the first 2 pediatric patients with abdominal angiosarcoma who were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) after neoadjuvant therapy. The first patient is alive with recurrent disease at 1-year follow-up and the second patient remains disease free after 1 year. CRS and HIPEC should be considered as a therapeutic option in the management of pediatric abdominal angiosarcomas. A multi-institutional international shared registry is needed to further evaluate the role of CRS and HIPEC in inducing remission of abdominopelvic angiosarcomas in the pediatric population.
| Original language | English (US) |
|---|---|
| Journal | Journal of Pediatric Hematology/Oncology |
| DOIs | |
| State | Accepted/In press - May 31 2018 |
Fingerprint
Keywords
- abdominal sarcoma
- HIPEC
- pediatric sarcoma
- pelvic angiosarcoma
- sarcoma
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology
Cite this
Novel Therapy for Pediatric Angiosarcoma With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. / Winer, Lindsey; Macedo, Francisco I.; Alfawaz, Abdullah; Sommariva, Antonio; Cecchetto, Giovanni; Neville, Holly L.; Möller, Mecker G.
In: Journal of Pediatric Hematology/Oncology, 31.05.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Novel Therapy for Pediatric Angiosarcoma With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
AU - Winer, Lindsey
AU - Macedo, Francisco I.
AU - Alfawaz, Abdullah
AU - Sommariva, Antonio
AU - Cecchetto, Giovanni
AU - Neville, Holly L.
AU - Möller, Mecker G.
PY - 2018/5/31
Y1 - 2018/5/31
N2 - The management of pediatric abdominopelvic angiosarcoma remains unclear due to limited clinical experience. Herein, we presented the first 2 pediatric patients with abdominal angiosarcoma who were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) after neoadjuvant therapy. The first patient is alive with recurrent disease at 1-year follow-up and the second patient remains disease free after 1 year. CRS and HIPEC should be considered as a therapeutic option in the management of pediatric abdominal angiosarcomas. A multi-institutional international shared registry is needed to further evaluate the role of CRS and HIPEC in inducing remission of abdominopelvic angiosarcomas in the pediatric population.
AB - The management of pediatric abdominopelvic angiosarcoma remains unclear due to limited clinical experience. Herein, we presented the first 2 pediatric patients with abdominal angiosarcoma who were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) after neoadjuvant therapy. The first patient is alive with recurrent disease at 1-year follow-up and the second patient remains disease free after 1 year. CRS and HIPEC should be considered as a therapeutic option in the management of pediatric abdominal angiosarcomas. A multi-institutional international shared registry is needed to further evaluate the role of CRS and HIPEC in inducing remission of abdominopelvic angiosarcomas in the pediatric population.
KW - abdominal sarcoma
KW - HIPEC
KW - pediatric sarcoma
KW - pelvic angiosarcoma
KW - sarcoma
UR - http://www.scopus.com/inward/record.url?scp=85048255764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048255764&partnerID=8YFLogxK
U2 - 10.1097/MPH.0000000000001231
DO - 10.1097/MPH.0000000000001231
M3 - Article
C2 - 29863582
AN - SCOPUS:85048255764
JO - Journal of Pediatric Hematology/Oncology
JF - Journal of Pediatric Hematology/Oncology
SN - 1077-4114
ER -